# Fibroblast Growth Factor (FGFs) / Fibroblast Growth Factor Receptor (FGFRs) Genetic as a Second-line Therapy for Recurrent / Progressive Gastric Cancer With INCB054828 and Paclitaxel a Study to Evaluate the Safety and Efficacy of Combination Therapy.

> **NCT05529667** · PHASE1,PHASE2 · COMPLETED · sponsor: **Yonsei University** · enrollment: 15 (actual)

## Conditions studied

- Fibroblast Growth Factors (FGFs)/Fibroblast Growth Factor Receptors (FGFRs) Genetic Aberration Gastric Cancer, INCB054828, Paclitaxel

## Interventions

- **DRUG:** INCB054828, Paclitaxel

## Key facts

- **NCT ID:** NCT05529667
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-27
- **Primary completion:** 2023-08-30
- **Final completion:** 2023-08-30
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2024-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05529667

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05529667, "Fibroblast Growth Factor (FGFs) / Fibroblast Growth Factor Receptor (FGFRs) Genetic as a Second-line Therapy for Recurrent / Progressive Gastric Cancer With INCB054828 and Paclitaxel a Study to Evaluate the Safety and Efficacy of Combination Therapy.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05529667. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*